Category: COPD

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk

RIDGEFIELD, Conn., Oct. 17, 2016 /PRNewswire/ — Boehringer Ingelheim today announced new data analyses from the Phase III TONADO® 1&2 trials that build upon existing evidence about the factors that increase the risk of a COPD exacerbation. These data were presented today at the…

GSK announce positive results from the COPD Salford Lung Study

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England Journal of Medicine (NEJM). This unique study, which reported headline results in May 2016, was designed to evaluate the effectiveness and safety of Relvar® Ellipta® in patients with chronic obstructive pulmonary disease (COPD), compared with their ‘usual care’ administered in an everyday clinical practice setting.

GSK’s triple COPD combination therapy meets two co-primary endpoints in phase III study

GlaxoSmithKline’s (GSK) investigational once-daily closed triple combination therapy was superior to AstraZeneca’s twice-daily Symbicort Turbohaler (budesonide/formoterol 400/12 mcg) in a phase III study in patients with chronic obstructive pulmonary disease (COPD).

Boehringer Ingelheim and HealthPrize Partner to Launch New Support Program for People Treating COPD With SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray

RIDGEFIELD, Conn. and NORWALK, Conn., June 8, 2016 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals Inc. and HealthPrize Technologies today announced the launch of RespiPoints™, a free online program that educates, engages, and rewards people who are treating their COPD…